SOAT1 and myeloproliferative disorder: The understanding of the development of MPN, mainly by unregulated activation of the JAK/STAT pathway and, hence, introduction of JAK inhibitors in the treatment of MPN, has fundamentally changed the management of MF patients before, during, and after HCT.